Department of General Surgery, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Lyon, France.
Department of Surgical Oncology, Zydus Hospital, Ahmedabad, India.
Ann Surg Oncol. 2023 Jun;30(6):3287-3299. doi: 10.1245/s10434-023-13242-8. Epub 2023 Feb 23.
Patients with advanced epithelial ovarian cancer who undergo incomplete surgery followed by six cycles of chemotherapy could benefit from second-look or consolidation cytoreductive surgery (CCRS). The primary goal of this study was to evaluate the overall survival (OS) in patients undergoing complete CCRS and the factors affecting survival. The secondary goal was to study the benefit of hyperthermic intraperitoneal chemotherapy (HIPEC) in these patients.
This was a retrospective analysis of 173 patients with CCRS with (n = 118) or without (n = 55) HIPEC treated at 12 French centers. Only patients having a completeness of cytoreduction (CC) 0/1 resection and a minimum of 5 years of follow-up were included. HIPEC was performed systematically for all patients except those treated at the four centers that did not perform HIPEC.
The median Peritoneal Cancer Index was 6 (range 0-33). Closed HIPEC was performed in 59 (34.1%) patients and open HIPEC was performed in 56 (32.3%) patients. Grade 3-4 complications occurred in 64 (36.9%) patients. The median OS was 35.67 months (95% confidence interval [CI] 29.8-46.1) and was significantly longer for CCRS + HIPEC (31.4 months without HIPEC and 42.5 months with HIPEC; p = 0.022). On multivariate analysis, closed HIPEC (hazard ratio [HR] 0.46, 95% CI 0.29-0.73; p < 0.001) resulted in a longer OS, and age > 65 years (HR 2.17, 95% CI 1.14-4.11; p = 0.018) and bowel resection (HR 1.98, 95% CI 1.27-3.08; p = 0.020) led to a shorter OS. On multivariate logistic regression analysis, closed HIPEC (odds ratio 0.18; p = 0.001) was associated with a lower risk of dying at 5 years.
CCRS was performed with an acceptable morbidity and resulted in good overall survival. The role of HIPEC in addition to CCRS should be evaluated in prospective, randomized studies and the closed technique prospectively compared with the open technique.
接受不完全手术和六轮化疗的晚期上皮性卵巢癌患者可能受益于二次探查或巩固性细胞减灭术(CCRS)。本研究的主要目的是评估行完全 CCRS 患者的总生存(OS)和影响生存的因素。次要目标是研究这些患者接受腹腔内热灌注化疗(HIPEC)的益处。
这是对在 12 个法国中心接受 CCRS 治疗的 173 例患者(n=118 例)或未接受 HIPEC 治疗的患者(n=55 例)进行的回顾性分析。仅纳入 CC 0/1 切除且随访时间至少 5 年的患者。除未行 HIPEC 的 4 个中心外,所有患者均行系统性 HIPEC。
腹膜肿瘤指数中位数为 6(范围 0-33)。59 例(34.1%)患者行闭式 HIPEC,56 例(32.3%)患者行开放式 HIPEC。3-4 级并发症发生率为 64 例(36.9%)。中位 OS 为 35.67 个月(95%置信区间[CI] 29.8-46.1),CCRS+HIPEC 组明显更长(无 HIPEC 为 31.4 个月,有 HIPEC 为 42.5 个月;p=0.022)。多变量分析显示,闭式 HIPEC(风险比[HR] 0.46,95%CI 0.29-0.73;p<0.001)可延长 OS,年龄>65 岁(HR 2.17,95%CI 1.14-4.11;p=0.018)和肠切除术(HR 1.98,95%CI 1.27-3.08;p=0.020)导致 OS 缩短。多变量逻辑回归分析显示,闭式 HIPEC(比值比 0.18;p=0.001)与 5 年死亡风险降低相关。
CCRS 具有可接受的发病率,并可带来良好的总生存。应在前瞻性随机研究中评估 HIPEC 除 CCRS 之外的作用,并前瞻性比较闭式技术与开放式技术。